InvestWiser

Newbury Pharmaceuticals AB

NEWBRYNasdaq StockholmHealthcareMarket value 59 m SEK
1.94SEK −3.7%
last day · Price as of 19 November 2026

The answer first

Does Newbury Pharmaceuticals beat the market?

Yes, Newbury Pharmaceuticals has beaten the market over the last year.

Newbury Pharmaceuticals+24.4%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 17% of Nordic stocks

    • Quality14
    • Value21
    • Trend64

    No. 140 of 195 in healthcare

Max for seven days

Follow Newbury Pharmaceuticals with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Newbury Pharmaceuticals

From today, at a price of 1.94 SEK. Write why you follow Newbury Pharmaceuticals, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Newbury Pharmaceuticals

Your first answer is free, no account needed.

Do you own Newbury Pharmaceuticals, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Newbury Pharmaceuticals and a few more. Free, no card.

Past year against the exchange and Super Stock
Newbury Pharmaceuticals+24.4%Stockholm (OMXSGI)+17.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Newbury Pharmaceuticals has risen 24.4% over the past year, including dividends.
  • Overall, Newbury Pharmaceuticals ranks better than 17% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 87.9%. The price is 84.6% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

17

Quality, value and trend together. Better than 17% of Nordic stocks.

No. 140 of 195 in healthcare

Quality14
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 181 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.56
  • Return on equityProfit divided by equity−116.9%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value21
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 96 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity2.9
  • P/SPrice divided by sales1.4
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend64
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−20.7%
  • 6 months+41.2%
  • 9 months+66.1%
  • 12 months+24.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+13.2%
3 years, per year
−18.6%
5 years, per year
–
Year to date
+68.3%
Largest fall, 3 years
−87.9%
From a peak to the bottom
From the peak now
−84.6%
How far the price is from the peak
Volatility, 1 year
139.1%
How much the price swings over a year
Beta, 1 year
1.47
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Newbury Pharmaceuticals

One fund we follow owns Newbury Pharmaceuticals. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Newbury Pharmaceuticals

Newbury Pharmaceuticals AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

See the full analysis of Newbury Pharmaceuticals.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market